Sam Lockhart

May 27, 2024 | medrxiv.org | Yajie Zhao |Sam Lockhart |Jimmy Liu |Xihao Li

J.L., A.C., Y.L., J.D., C.B-D. and R.S. are employees and stockholders of GSK. J.R.B.P. and E.J.G. are employees and shareholders of Insmed. J.R.B.P. receives research funding from GSK. Y.Z. is a UK University worker at GSK. S.O.R. has undertaken remunerated consultancy work for Pfizer, Third Rock Ventures, AstraZeneca, NorthSea Therapeutics and Courage Therapeutics. The other authors declare no competing interests.

Apr 29, 2024 | biorxiv.org | Sam Lockhart |Milan Muso |Ilona Zvetkova |Brian Lam

New Results Damaging mutations in LXRα uncouple lipogenesis from hepatotoxicity and implicate hepatic cholesterol sensing in human liver health Sam M Lockhart, Milan Muso, Ilona Zvetkova, Brian Lam, Alessandra Ferrari, Erik Schoenmakers, Katie Duckett, Jack Leslie, Beatriz Romartinez-Alonso, John Tadross, Raina Jia, Eugene Gardner, Katherine Kentistou, Yajie Zhao, Felix Day, Alexander Morseburg, Kara Rainbow, Deb Rimmington, Matteo Mastantuoni, James Harrison, Meritxell Nus, Khalid Guma'a,...

Dec 15, 2023 | newsbreak.com | Sam Lockhart

By signing up for our newsletter, you agree to our Terms of Use and Privacy Policy